BCL-2 (B-cell lymphoma 2) Inhibitors Industry- Regional Synopsis
North American Market Forecast
North America industry is poised to account for largest revenue share of 56% by 2037, impelled by the increasing product approvals. For instance, in 2020, The Food and Drug Administration approved venetoclax (VENCLEXTA, AbbVie Inc., and Genentech Inc.) after it was granted accelerated approval for use in 2018. Furthermore, the recommended dose of venetoclax is determined by the combination regimen that can be used in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly diagnosed acute myeloid leukemia (AML) in people 75 years of age or older.
European Market Statistics
The Europe BCL-2 inhibitors market is estimated to be the second largest, during the forecast timeframe led by increasing health awareness. Moreover, Europe has developed several innovative and effective solutions to promote good health and well-being, and to create awareness about the importance of healthy lifestyles. This, as a result, may drive demand for BCL-2 inhibitors for several diseases prevailing in the region.
 Inhibitors Market Size.webp)
